Versant Capital Management’s Relay Therapeutics RLAY Stock Holding History

Versant Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.1K	Hold	559	–	–	﹤0.01%	2260
2026 Q2	$10.5K	Buy	559 +66	+13%	+$958	﹤0.01%	2215
2026 Q1	$4.9K	Hold	493	–	–	﹤0.01%	2387
2025 Q4	$4.17K	Hold	493	–	–	﹤0.01%	2315
2025 Q3	$2.57K	Hold	493	–	–	﹤0.01%	2367
2025 Q2	$1.71K	Sell	493 -965	-66%	-$2.87K	﹤0.01%	2412
2025 Q1	$3.82K	Buy	+1,458	New	+$5.71K	﹤0.01%	2124
2024 Q3	–	Sell	-309	Closed	-$2.02K	–	2069
2024 Q2	$2.02K	Buy	309 +231	+296%	+$1.58K	﹤0.01%	1510
2024 Q1	$647	Hold	78	–	–	﹤0.01%	1641
2023 Q4	$859	Buy	+78	New	+$658	﹤0.01%	1558
2023 Q3	–	Sell	-90	Closed	-$1.13K	–	2037
2023 Q2	$1.13K	Buy	+90	New	+$1.12K	﹤0.01%	1557

Other funds holding RLAY

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Versant Capital Management's RLAY Position: Q3 2026 in Review

Versant Capital Management held its Relay Therapeutics (RLAY) position steady in Q3 2026 at 559 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Versant Capital Management first reported a position in RLAY in Q2 2023 and has held it in 11 quarters since. The position peaked at $10.5K in Q2 2026. 114 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.

Versant Capital Management held 559 shares of Relay Therapeutics worth $10.1K as of Q3 2026.
Versant Capital Management left its Relay Therapeutics share count unchanged in Q3 2026.
Relay Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2260 holding.
Versant Capital Management first reported a position in Relay Therapeutics in Q2 2023 and has held it in 11 quarters since.
Versant Capital Management's Relay Therapeutics position peaked at $10.5K in Q2 2026.
114 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.